Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma

Creative Commons License

Batirel H. F., METİNTAŞ M., Caglar H. B., AK G., Yumuk P. F., Ahiskali R., ...More

Journal of Thoracic and Cardiovascular Surgery, vol.155, no.6, pp.2724-2733, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 155 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1016/j.jtcvs.2017.12.131
  • Journal Name: Journal of Thoracic and Cardiovascular Surgery
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2724-2733
  • Keywords: malignant pleural mesothelioma, macroscopic complete resection
  • Istanbul Medipol University Affiliated: Yes


Objective: Macroscopic complete resection (MCR) is the recommended surgical strategy in malignant pleural mesothelioma. Our objective was to analyze whether MCR influences survival in malignant pleural mesothelioma. Methods: Between 2002 and 2016, 154 patients underwent pleurectomy decortication (n = 90), extrapleural pneumonectomy (n = 42), or exploratory/diagnostic procedures (n = 22) in a single institution. Patient data were recorded in a prospective database. Patients who underwent surgical resection (n = 132) were analyzed according to MCR as a whole group and after propensity score matching based on gender, age, histology, clinical T and N status, adjuvant chemotherapy, and trimodality treatment. Kaplan-Meier survival and univariate and multivariate analyses were performed. Results: Median age was 56 years (range, 26 to 80 years) and 62 were women. One hundred ten had epithelioid histology. MCR was achieved in 75 patients (49%). In-hospital mortality was seen in 7 patients (4.5%). Preoperative chemotherapy was applied in 32 patients. One hundred thirty-three patients underwent adjuvant treatment (45 had chemoradiation). Mean follow-up was 21 ± 19 months. Overall median survival, 2-year, and 5-year survivals were 18.1 months, 36%, and 16%, respectively. There was no difference in median survival between patients who underwent MCR (21.4 months) and who did not (16.3 months) (P =.6). Following propensity score matching (23 patients in each group), median survivals were similar (13.3 vs 14.2 months; P =.63). Conclusions: MCR was not associated with improved survival in malignant pleural mesothelioma. We need to clearly define MCR and identify subgroups of patients who would benefit from this principle because minimal versus extensive and location of gross residual disease may have different influences on survival.